Pramar Yashoda V, Mandal Tarun K, Bostanian Levon A, Le Giang, Morris Tommy C, Graves Richard A
College of Pharmacy, Xavier University of Louisiana, New Orleans, Louisiana.
Int J Pharm Compd. 2020 Sep-Oct;24(5):413-419.
Allopurinol is an orally administered inhibitor of xanthine oxidase used primarily in the treatment of hyperuricemia associated with gout. Allopurinol reduces serum and urinary uric acid concentrations. Its use should be individualized for each patient. The dosage of allopurinol to accomplish full control of gout and to lower serum uric acid to normal or near-normal levels varies with the severity of the disease, and needs to be flexible to permit precise, customized dose titration for individual patients. This flexibility is readily achieved using an oral liquid dosage form. However, no commercial liquid dosage form of allopurinol currently exists. Allopurinol is commercially available as 100-mg and 300-mg scored tablets. An extemporaneously compounded suspension from pure drug powder or commercial tablets would provide a convenient option to meet unique patient needs. The purpose of this study was to determine the physicochemical stability of extemporaneously compounded allopurinol suspensions in the PCCA Base SuspendIt. This base is a sugar-free, paraben-free, dye-free, and gluten-free thixotropic vehicle containing a natural sweetener obtained from the monk fruit. The study design included two allopurinol concentrations to provide stability documentation over a bracketed concentration range for eventual use by compounding pharmacists. A robust stability-indicating ultra-performance liquid chromatography assay for the determination of the chemical stability of allopurinol in SuspendIt was developed and validated. Suspensions of allopurinol were prepared in SuspendIt at 10.0-mg/mL and 20.0-mg/mL concentrations, selected to represent a range within which the drug is commonly dosed. Samples were stored in plastic amber prescription bottles at two temperature conditions (5°C and 25°C). Samples were assayed initially and at the following time points: 7 days, 14 days, 30 days, 45 days, 60 days, 88 days, 120 days, and 182 days. Physical data such as pH, viscosity, and appearance were also noted. All measurements were obtained in triplicate. A stable extemporaneous product is defined as one that retains at least 90% of the initial drug concentration throughout the sampling period. The study showed that allopurinol concentrations did not go below 93% of the label claim (initial drug concentration) at both temperatures studied. Viscosity and pH values also did not change significantly. This study demonstrates that allopurinol is physically and chemically stable in SuspendIt for 180 days in the refrigerator and at room temperature, thus providing a viable, compounded alternative for allopurinol in a liquid dosage form, with an extended beyond-use-date to meet patient needs.
别嘌醇是一种口服的黄嘌呤氧化酶抑制剂,主要用于治疗与痛风相关的高尿酸血症。别嘌醇可降低血清和尿液中的尿酸浓度。其使用应针对每位患者进行个体化调整。实现痛风的完全控制并将血清尿酸水平降至正常或接近正常水平所需的别嘌醇剂量因疾病严重程度而异,并且需要灵活调整,以便为个体患者进行精确的、定制化的剂量滴定。使用口服液体制剂很容易实现这种灵活性。然而,目前尚无别嘌醇的商业液体制剂。别嘌醇有100毫克和300毫克刻痕片的商业制剂。由纯药物粉末或市售片剂临时配制的混悬液将为满足患者的独特需求提供一种方便的选择。本研究的目的是确定在PCCA Base SuspendIt中临时配制的别嘌醇混悬液的物理化学稳定性。该基质是一种无糖、无对羟基苯甲酸酯、无染料且无麸质的触变载体,含有从罗汉果中提取的天然甜味剂。研究设计包括两种别嘌醇浓度,以便在一个涵盖的浓度范围内提供稳定性记录,供配制药剂师最终使用。开发并验证了一种用于测定别嘌醇在SuspendIt中的化学稳定性的稳健的稳定性指示超高效液相色谱法。别嘌醇混悬液在SuspendIt中分别以10.0毫克/毫升和20.0毫克/毫升的浓度配制,这两个浓度代表了该药物常用的给药浓度范围。样品储存在塑料琥珀色处方瓶中,置于两种温度条件下(5℃和25℃)。样品在初始时以及以下时间点进行检测:7天、14天、30天、45天、60天、88天、120天和182天。还记录了诸如pH值、粘度和外观等物理数据。所有测量均重复进行三次。一种稳定的临时产品定义为在整个采样期间至少保留初始药物浓度90%的产品。研究表明,在所研究的两种温度下,别嘌醇浓度均未低于标签标示量(初始药物浓度)的93%。粘度和pH值也没有显著变化。本研究表明,别嘌醇在SuspendIt中于冰箱和室温下180天内物理和化学性质稳定,从而为别嘌醇提供了一种可行的液体制剂替代方案,其有效期延长,可满足患者需求。